Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2007-10-17
2010-10-05
Bunner, Bridget E (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C514S012200
Reexamination Certificate
active
07807143
ABSTRACT:
Methods and compositions for the enteral treatment of autoimmune disease such a multiple sclerosis with polypeptide therapeutics. Enteral therapeutics comprise monomeric alpha-MSH polypeptides such as ACTH. Therapeutic formulations of the invention may be used to reduce the incidence or severity of autoimmune disease. For instance methods for the oral treatment of multiple sclerosis with alpha-MSH and ACTH are described.
REFERENCES:
patent: 2904471 (1959-09-01), Kuehl, Jr.
patent: 2992165 (1961-07-01), Thompson
patent: 4554101 (1985-11-01), Hopp
patent: 4874744 (1989-10-01), Nordlund et al.
patent: 5028592 (1991-07-01), Lipton
patent: 5157023 (1992-10-01), Lipton
patent: 5359030 (1994-10-01), Ekwuribe
patent: 5674839 (1997-10-01), Hruby et al.
patent: 5714576 (1998-02-01), Hruby et al.
patent: 6338834 (2002-01-01), Jurisson et al.
patent: 7169603 (2007-01-01), Hedley et al.
patent: 2002/0193332 (2002-12-01), Hedley
patent: 2005/0239170 (2005-10-01), Hedley et al.
patent: 2007/0185030 (2007-08-01), Brod
patent: 3345358 (1985-06-01), None
patent: 3731875 (1989-03-01), None
patent: 0146113 (1985-06-01), None
patent: WO 02/06316 (2002-01-01), None
patent: WO 2005/072271 (2005-08-01), None
patent: WO 2005/123107 (2005-12-01), None
patent: WO 2006/021814 (2006-03-01), None
PCT International Preliminary Report on Patentability, issued in International Application No. PCT/US2007/081656, mailed Apr. 30, 2009.
Sandman et al., “An analog of MSH/ACTH 4-9 enhances interpersonal and environmental awareness in mentally retarded adults,”Peptides, 1:109-114, 1980.
International Search Report and Written Opinion issued in International Application No. PCT/US2007/081656, dated May 19, 2008.
Brod et al., “Ingested (oral) alpha-MSH inhibits acute EAE,”Cytokine, 39(1):4, 2007.
Brod et al., “Ingested (oral) alpha-MSH inhibits acute EAE,”Journal of Neuroimmunology, 193:106-112, 2008.
Rajora et al., “Alpha-MSH modulates experimetnal inflammatory bowel disease,”Peptides, 18(3):381-385, 1997.
Yin et al., “Generation of expression constructs that secrete bioactive alpha-MSH and their use ni the treatment of experimetnal autoimmune encephalomyelitis,”Gene Therapy, 10(4):348-355, 2003.
U.S. Appl. No. 08/844,731, filed Apr. 21, 1997, Brod.
Bergh et al., “Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis—Reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations,”BMC Neurology, 6:19, 2006.
Brod and Burns, “Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferons,”Neurology. 44:1144-1148, 1994.
Brod et al., “Oral administration of human or murine interferon alpha suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis,”J Neuroimmunol. 58:61-69, 1995.
Filippini et al., “Corticosteroids or ACTH for acute exacerbations in multiple sclerosis,”Cochrane Database Syst. Rev., 4:CD001331, 2000.
Hoggard et al., “Peripherally administered [Nle4,D-Phe7]-alpha-melanocyte stimulating hormone increases resting metabolic rate, while peripheral agouti-related protein has no effect, in wild type C57BL/6 and ob/ob mice,”J. Mol. Endocrinology, 33:693-703, 2004.
Luger et al., “New insights into the functions of alpha-MSH and related peptides in the immune system,”Ann N Y Acad Sci., 994:133-140, 2003.
Mahmood et al., “Selection of the first-time dose in humans: comparison of different approaches based on interspecies scaling of clearance,”J. Clin. Pharmacol., 43:692-697, 2003.
McDonold et al., “Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis,”Ann. Neurol., 50:121-127, 2001.
Miranda and Alewood, “Accelerated chemical synthesis of peptides and small proteins,”Proc. Natl. Acad. Sci. USA, 96:1181-1186, 1999.
Moustafa et al., “Inhibition of tumor necrosis factor-alpha stimulated NFkappaB/p65 in human keratinocytes by alpha-melanocyte stimulating hormone and adrenocorticotropic hormone peptides,”J. Invest. Dermatol., 119:1244-1253, 2002.
Namba et al., “Induction of regulatory T cells by the immunomodulating cytokines alpha-melanocyte-stimulating hormone and transforming growth factor-beta2,”J Leukoc Biol., 72:946-952, 2002.
Peters, “The Self-Similarity of the Melanocortin System,”Endocrinology, 146:529-531, 2005.
Scholzen et al., “alpha-Melanocyte Stimulating Hormone Prevents Lipopolysaccharide-Induced Vasculitis by Down-Regulating Endothelial Cell Adhesion Molecule Expression,”Endocrinology, 144:360-370, 2003.
Taylor and Namba, “In vitro induction of CD25+ CD4+ regulatory T cells by the neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH),”Immunol Cell Biol., 79:358-367, 2001.
Taylor et al., “Neuropeptide regulation of immunity. The immunosuppressive activity of alpha-melanocyte-stimulating hormone (alpha-MSH),”Ann N Y Acad Sci., 917:239-247, 2000.
Taylor, “Modulation of Regulatory T Cell Immunity by the Neuropeptide Alpha-Melanocyte Stimulating Hormone,”Cell Mol Biol(Noisy-le-grand), 49:143-149, 2003.
Van der Zee et al., “alpha-MSH and Org.2766 in peripheral nerve regeneration: different routes of delivery,”Eur. J. Pharmacol., 147:351-357, 1988.
Bunner Bridget E
Fulbright & Jaworski LLP
Hamud Fozia M
Research Development Foundation
LandOfFree
Alpha-MSH therapies for treatment of autoimmune disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha-MSH therapies for treatment of autoimmune disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha-MSH therapies for treatment of autoimmune disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4172667